BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tyruko (natalizumab-sztn) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tyruko (natalizumab-sztn)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05418010-7600@assetmemo.bio
DTSTAMP:20261121T005037Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tyruko (natalizumab-sztn): Phase 2 readout est. (NCT05418010)
DESCRIPTION:Tyruko (natalizumab-sztn)\, phase 2\, Multiple Sclerosis.\nStud
 y: Natalizumab for the Treatment of People With Inflammatory Demyelination
  Suggestive of Multiple Sclerosis\, or Definite Multiple Sclerosis\, at Fi
 rst Presentation (AttackMS)\nEstimated primary completion: 31 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tyruko-natalizumab-
 sztn#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05418010
URL:https://assetmemo.bio/drug/tyruko-natalizumab-sztn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
